Business Trends– category –
-
Varda Space Raises $187 Million, Joins BioOrbit to Advance Microgravity Drug Manufacturing with Goal of Human Application within 5 Years
CNN Business / The Pharmaceutical Journal / Facebook / Varda Space USA Overview Varda Space Industries has raised $187 million to accelerate the commercialization of drug manufacturing in microgravity, alongside companies like BioOrbit. ... -
U.S. Space Force Awards $981 Million Next-Gen Training Technology Contracts to 15 Companies
SoCo Digest USA Overview The U.S. Space Force has awarded contracts worth up to $981 million to 15 companies, including York Space Systems, Lockheed Martin Space, Sierra Space, Boeing, and Northrop Grumman, for the development of next-ge... -
Genentech and DualityBio Forge $1B+ Partnership to Accelerate Novel ADC Payloads, Combat Resistance
Fierce Biotech USA Overview Roche's Genentech has announced a significant collaboration with DualityBio, a deal potentially exceeding $1 billion, aimed at developing next-generation Antibody-Drug Conjugates (ADCs). This partnership will ... -
Polymeric Nanoparticles Unlock New Frontiers in Drug Delivery, Gene Therapy, and Medical Imaging
Nanbiosis Spain Overview Polymeric nanoparticles are emerging as a highly versatile and promising platform in nanomedicine, poised to revolutionize areas such as drug delivery, gene therapy, and medical imaging. Their customizable nature... -
Logic-Gated Bispecific ADCs Break Toxicity Barrier, Unleash Thousands of New Cancer Targets
Drug Discovery News USA Overview A novel logic-gated platform for bispecific antibody-drug conjugates (bsADCs) shows promise in unlocking thousands of previously inaccessible cancer targets for therapeutic development. By simultaneously ... -
Smart Hydrogel-Nanoparticle Platforms Pioneer Precision Drug Delivery and TME Modulation in Breast Cancer
ACS Publications USA Overview A recent paper in ACS Publications unveils a smart hydrogel-nanoparticle platform poised to revolutionize breast cancer treatment through precise drug delivery and tumor microenvironment (TME) modulation. Th... -
Unlocking TPD’s Promise: Nanomedicine and Programmable Proximity Platforms Revolutionize Degrader Delivery
MDPI Switzerland Overview Nanomedicine and programmable proximity platforms are emerging as pivotal solutions to the delivery challenges inherent in targeted protein degradation (TPD) technologies. Degrader molecules like PROTACs often f... -
Redefining Colorectal Cancer Treatment: Breakthroughs in Bispecific Antibodies and ADCs
MDPI Switzerland Overview Bispecific antibodies (bsAbs) and antibody-drug conjugates (bsADCs) are ushering in a new era for colorectal cancer (CRC) treatment, offering solutions to challenges like tumor heterogeneity and drug resistance.... -
Pin Therapeutics Unveils Oral CK1α Molecular Glue Degrader PIN-5018 for Adenoid Cystic Carcinoma at China TPD Forum, Phase 1 Underway Targeting FDA Accelerated Approval
Korea Biomedical Review South Korea Overview Pin Therapeutics presented PIN-5018, an oral CK1α-selective molecular glue degrader for adenoid cystic carcinoma (ACC), derived from its proprietary PinMARS platform, at the China Targeted Pro... -
Oligonucleotide Drug Delivery Shifts Beyond Liver-Targeting to Tissue-Specific Approaches for Muscle and CNS
GlobeNewswire Unknown Overview Oligonucleotide drug delivery is evolving significantly, moving from traditional liver-targeted strategies to tissue-specific approaches for extrahepatic organs like muscle and the central nervous system (C...
